Abstract
Background Approximately 1 in 4 children who sustain an acquired brain injury (ABI) have attention difficulties impacting education, employment, and community participation. These difficulties arise from dysfunction in attention-related brain networks, incentivising the use of transcranial direct current stimulation (tDCS).
Objective/Hypothesis We investigated whether a single tDCS session improved attention following childhood ABI and whether baseline structural connectivity (sc), functional connectivity (fc), attention, and/or simulated electric fields (E-field) explained variability in response.
Methods In a randomised, single-blind, within-subject, sham-controlled trial, 15 children with ABI (mean 12.7 years) and 15 healthy controls (HCs) received three single tDCS sessions (1mA dorsolateral prefrontal cortex [dlPFC], 1mA inferior frontal gyrus [IFG], sham; 20min) during gamified attention training. We examined post-intervention changes in attention according to flanker and stop signal reaction time (RT). We used multi-modal analyses (high-density electroencephalography [HD-EEG], diffusion tensor imaging, magnetic resonance imaging) to investigate inter-individual variability in tDCS response, according to associations between RT change and baseline fc, sc, attention, and E-fields.
Results Although no effect of active versus sham tDCS was found overall, participants with lower theta or higher gamma default mode network connectivity and poorer attention at baseline showed greater response to tDCS. Higher E-fields were associated with greater response. No serious adverse effects occurred.
Conclusions A single tDCS session targeting dlPFC or IFG did not improve attention following pediatric ABI. We demonstrated how HD-EEG source-based connectivity may be used to personalise tDCS. Future research should explore whether personalization, and/or repeated tDCS sessions can improve attention following pediatric ABI.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This was not deemed a clinical trial by University of Queensland IRB due to the investigational (non treatment) nature. This was registered on OSF prior to commencement: osf.io/b43nh.
Funding Statement
This work was supported by a Herston Imaging Research Facility (HIRF) Pilot Scheme Grant and University of Queensland Child Health Research Centre Small Grant. Michael Craven and Madeleine Groom are supported by the National Institute for Health and Care Research (NIHR) Nottingham Biomedical Research Centre and the NIHR MindTech MedTech Co-operative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with Good Clinical Practice and ethical approval was received by the University of Queensland (HREC/21/QCHQ/73034).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.